Pfizer eyes other large pharmaceutical companies for acquisitions

NEW YORK Pfizer’s CEO said his company wants to expand its portfolio of acquired companies, and no company is too big, according to published reports.

Jeff Kindler told the Financial Times that the drug maker would consider purchasing a large stake in a major pharmaceutical company to increase its revenues. Some have speculated that this could mean a purchase of Amgen or Gilead Sciences or a merger with a larger company such as Bristol-Myers Squibb or Wyeth.

The company’s profits are in danger of falling in 2011, when the blockbuster anti-cholesterol drug Lipitor (atorvastatin calcium) becomes open to generic competition. The drug has annual sales of about $13 billion.

Login or Register to post a comment.